Genmab AS (GMAB)vsRevolution Medicines Inc (RVMD)
GMAB
Genmab AS
$32.47
+0.74%
HEALTHCARE · Cap: $20.65B
RVMD
Revolution Medicines Inc
$205.11
+0.66%
HEALTHCARE · Cap: $44.44B
Smart Verdict
WallStSmart Research — data-driven comparison
Genmab AS generates 556639% more annual revenue ($4.13B vs $742,000). GMAB leads profitability with a 19.1% profit margin vs 0.0%. GMAB earns a higher WallStSmart Score of 53/100 (C-).
GMAB
Buy53
out of 100
Grade: C-
RVMD
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+48.6%
Fair Value
$58.54
Current Price
$32.47
$26.07 discount
Intrinsic value data unavailable for RVMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 35.2%
Revenue surging 24.9% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Weak financial health signals
Expensive relative to growth rate
Trading at 16.9x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : GMAB
The strongest argument for GMAB centers on Operating Margin, Revenue Growth. Profitability is solid with margins at 19.1% and operating margin at 35.2%. Revenue growth of 24.9% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : GMAB
The primary concerns for GMAB are P/E Ratio, Altman Z-Score, Piotroski F-Score.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
GMAB profiles as a growth stock while RVMD is a value play — different risk/reward profiles.
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
GMAB is growing revenue faster at 24.9% — sustainability is the question.
GMAB generates stronger free cash flow (48M), providing more financial flexibility.
Bottom Line
GMAB scores higher overall (53/100 vs 24/100), backed by strong 19.1% margins and 24.9% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Genmab AS
HEALTHCARE · BIOTECHNOLOGY · USA
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
Visit Website →Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?